Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes

Diabetic Medicine

Volumn 25, Issue 1, 2008, Pages 37-44

  Aversa, A ^a   Vitale, C ^b   Volterrani, M ^b   Fabbri, A ^c   Spera, G ^a   Fini, M ^b   Rosano, G M C ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Diabetes; Endothelial dysfunction; Erectile dysfunction; Phosphodiesterase type 5; Rehabilitation

Indexed keywords

C REACTIVE PROTEIN; GLYCERYL TRINITRATE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PHOSPHODIESTERASE V; PLACEBO; SILDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ERECTILE DYSFUNCTION; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CELL ADHESION MOLECULES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 38049187090     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02298.x     Document Type: Article

References (28)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. J Am Med Assoc 1979 241 : 2035 2038.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 339 : 229 234.
3. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV et al. Diabetes and cardiovascular disease: a statement for health professionals from the American Heart Association. Circulation 1999 100 : 1134 1146.
4. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000 101 : 1899 906.
5. Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005 258 : 250 256.
6. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998 338 : 1397 1404.
7. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998 159 : 2164 2171.
8. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM et al. Sildenafil. an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996 8 : 47 52.
9. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995 75 : 725 748.
10. Aversa A, Bruzziches R, Pili M, Spera G. Phosphodiesterases type 5 inhibitor drugs in the treatment of erectile dysfunction. Curr Pharm Des 2006 12 : 3467 3484.
11. Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005 111 : 2518 2524.
12. Behr-Roussel D, Gorny D, Mevel K, Caisey S, Bernabe J, Burgess G et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 2005 47 : 87 91.
13. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005 47 : 214 222.
14. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999 11 : 319 326.
15. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007 19 : 200 207.
16. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002 25 : 1336 1339.
17. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for 1 year: a randomized trial. Asian J Androl 2007 9 : 134 141.
18. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005 111 : 1601 1610.
19. Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A et al. Cardioprotection with phosphodiesterase-5 inhibition - a novel preconditioning strategy. J Mol Cell Cardiol 2004 36 : 165 173.
20. Devan BD, Sierra-Mercado D Jr., Jimenez M, Bowker JL, Duffy KB, Spangler EL et al. Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol Biochem Behav 2004 79 : 691 699.
21. Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol 2005 68 : 226 232.
22. Yavuzgil O, Altay B, Zoghi M, Gurgun C, Kayikcioglu M, Kultursay H. Endothelial function in patients with vasculogenic erectile dysfunction. Int J Cardiol 2005 103 : 19 26.
23. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high-fat-fed conscious mice. Diabetes 2007 56 : 1025 1033.
24. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005 11 : 214 222.
25. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005 353 : 2148 2157.
26. Schermuly RT, Inholte C, Ghofrani HA, Gall H, Weissmann N, Weidenbach A et al. Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respir Res 2005 20 6 : 76 81.
27. Cook S, Scherrer U. Insulin resistance, a new target for nitric oxide delivery drugs. Fundam Clin Pharmacol 2002 16 : 441 453.
28. Mino G. Reverence values of crythrocyte sedimentation rate of adult healthy subjects. Yale J Biol Med 2002 75 : 65 71.